Medrack.Health Oral cancer medicine guide Commonly prescribed forMetastatic and non-metastatic castration-resistant prostate cancer
This page explains the medicine in plain language and how a prescription-led access request is assessed for a patient in Ghana. Treatment decisions always stay with the treating oncology team.
We do not display prices publicly. If a request is eligible, the available medicine details, documentation and any further arrangements are confirmed in writing for that individual case.
Enzalutamide is the active ingredient in Xtandi, used for advanced prostate cancer (androgen-receptor inhibitor). It is supplied as a capsule in strengths of 40 mg, made to WHO-GMP standards by established Indian manufacturers.
| Sold in India as | Manufacturer |
|---|---|
| Bdenza | BDR Pharmaceuticals |
| Glenza | Glenmark |
Do not make a treatment or payment decision from a public product page. Discuss treatment with the patient's clinician and wait for written case information.
Enzalutamide is an androgen-receptor inhibitor. It blocks testosterone from binding to and activating prostate-cancer cells, and stops the receptor entering the cell nucleus - halting growth signals.
Usually taken once daily, with or without food, as directed by the oncologist. Taken continuously while effective.
Available strengths: 40 mg. Always follow your own doctor's instructions.
Common or notable side effects include:
This is not a complete list. Read the patient leaflet and seek medical advice for anything severe or unexpected.
Specialist supervision essential. Tell your doctor about any seizure history. Numerous drug interactions - share your full medication list. Supplied via our assisted process.
Enzalutamide and Xtandi contain the same active ingredient, Enzalutamide, at the same strengths (40 mg), and work in exactly the same way. Xtandi is the originator brand; Enzalutamide is the generic equivalent. Generic substitution, brand selection and patient suitability are clinical decisions that should be made with the treating clinician. If a request is eligible, the proposed product information is confirmed in writing before any next step.
Generic medicine information is assessed in the context of the patient’s prescription, requested strength and destination. The treating clinician should remain the decision-maker for any generic substitution. Availability and product details are not assumed from this public page and are confirmed only if an individual case is eligible.
A son, daughter, spouse or another caregiver may start a request on behalf of the patient, including from another country. Enter the patient's name exactly as it appears on the prescription. The prescription should come from the patient’s treating clinician; we then assess whether an appropriate route may be available for Ghana.
Submit a request with the medicine, strength, patient details and destination. We assess the prescription status and whether an appropriate route may be available. If a case is eligible, the proposed medicine details, documentation, total cost and delivery options are confirmed in writing before you decide whether to proceed.
Medrack.Health is currently focused on Ghana and Kenya. It does not guarantee availability, import approval, customs clearance, delivery timing or supply from a public product page.
This medicine uses our assisted process: your request and prescription status are assessed before any possible next step is discussed.
It is the same molecule to WHO-GMP standards, supplied with manufacturer and batch details through our pharmacist-reviewed assisted process.
This page is general information, not medical advice. Always consult your own doctor about whether Enzalutamide is right for you.
Help us improve this guide. Please do not include prescription, diagnosis or other personal health information.